8-K filing — Ocugen, Inc. (OCGN)
Filed: 2026-08-06 AccNo: 0001104659-26-091691 Size: 2 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
FDA Grants RMAT Designation To Ocugen’s Investigational Product OCU410 For Treatment Of Geographic Atrophy, Secondary To Dry Age-Related Macular Degeneration
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 29, 2026, 11:13 AM
- Checked
- Jul 29, 2026, 11:12 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Ocugen Q2 EPS $(0.07) Misses $(0.05) Estimate, Sales $1.488M Beat $888.833K Estimate
Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. This is a 40 percent decrease over losses of $(0.05) per share from the same
Read original at benzingaOcugen To Enter License Agreement With Roots Pharmaceutical For Rights To OCU400, Its Novel Modifier Gene Therapy For Retinitis Pigmentosa, In The Middle East And North Africa
Cumulative sales milestones up to $255 million and modest upfront/near-term development milestonesRoyalties equaling 22% of net salesOcugen to manufacture and supply OCU400
Read original at benzinga